Tana Takacova | Clinical Medicine | Best Researcher Award

Dr. Tana Takacova | Clinical Medicine | Best Researcher Award

Oncologist | Asklepios Klinik Altona | Germany

Tana Takacova is a physician-scientist specializing in hematology, oncology, and internal medicine with a distinguished academic and clinical trajectory across leading European research and tertiary care institutions. Her expertise spans immuno-oncology, molecular oncology, hematologic malignancies, and translational cancer research, supported by advanced training in oncology from a major German university and extensive postgraduate exposure to molecular biosciences in the United States. She has held clinical roles in prominent university-affiliated hospitals, progressing through multidisciplinary departments including hematology, oncology, palliative medicine, internal medicine, rheumatology, nephrology, gastroenterology, and cardiology, complemented by ongoing training as a prehospital emergency physician. Dr. Takacova has contributed to multiple international research collaborations across Germany, Denmark, Italy, and Slovakia, advancing knowledge in cancer genetics, circulating tumor DNA, oncolytic virus-checkpoint inhibitor synergies, renal cell carcinoma biomarkers, and therapy response prediction. Her peer-reviewed scholarship includes original research articles, systematic reviews, and case-based contributions in oncology and immunology, with additional manuscripts in review and development, reflecting a sustained commitment to evidence-based innovation and emerging therapeutic paradigms in precision oncology. She has presented at international oncology and pharmacology congresses and participates in global research networks and professional societies, reinforcing a truly international academic presence. Her work integrates advanced laboratory skills, clinical trial supervision, systematic review methodology, and bioinformatics-supported analysis, underscoring strong translational orientation. She has been recognized by competitive research fellowships and academic awards and contributes to open-access medical knowledge through educational initiatives such as a freely accessible hematology atlas. Fluent in multiple languages and trained across diverse health systems, she brings a global perspective, resilience in high-pressure environments, and a collaborative approach to clinical care and research leadership, driven by a commitment to advancing cancer diagnostics, therapeutic precision, and equitable patient outcomes worldwide. She has 34 citations from 4 documents with an h-index of 2.

Profile: Scopus

Publications

1. Tana Takacova (2025). Paraneoplastic papillitis as a precursor to colon carcinoma: A case of unexpected vision loss leading to early cancer detection. Oncology Research and Treatment.

Miguel Garcia-Gonzalez | Translational Research | Innovative Research Award

Dr. Miguel Garcia-Gonzalez | Translational Research | Innovative Research Award

Research group leader | FIDIS/IDIS | Spain

Dr. Miguel García González is a distinguished biomedical researcher and Group Leader at the Instituto de Investigación Sanitaria de Santiago (IDIS/CHUS) in Spain, specializing in Molecular Genetics and Developmental Biology of Kidney Diseases. He earned his Ph.D. in Molecular Biology from the University of Santiago de Compostela, where he developed a strong foundation in genetics, molecular mechanisms, and translational nephrology. His research focuses on understanding the genetic and molecular bases of polycystic kidney disease (PKD) and related hereditary disorders, integrating genomic, cellular, and developmental biology approaches to identify novel therapeutic targets. Dr. García González has authored more than 40 peer-reviewed publications in high-impact journals such as Nature Medicine, PNAS, Kidney International, and Human Molecular Genetics, contributing significantly to the field’s understanding of renal pathophysiology. His work has received numerous national and international research grants and awards, recognizing his excellence in scientific innovation and mentorship. He actively participates in editorial and peer-review roles for several leading journals in nephrology and molecular biology, further influencing the direction of biomedical research. In addition to his research contributions, Dr. García González is deeply committed to training young scientists, supervising doctoral and postdoctoral researchers, and fostering interdisciplinary collaboration across clinical and molecular domains. His pioneering work continues to advance precision medicine approaches in nephrology, bridging basic science discoveries with clinical applications aimed at improving outcomes for patients with genetic kidney diseases. He has 1913 citations from 50 documents with an h-index of 20.

Profiles: Google Scholar | Scopus | ORCID

Publications

1. A comparative proteomic, transcriptomic and glycomic analysis of extracellular vesicle isolation techniques highlights ExoGAG efficiency for a more complete identification of breast milk molecular signaling pathways. (2025). Cell Communication and Signaling.

2. Therapeutic opportunities in polycystic kidney and liver disease through extracellular matrix dynamics. (2025). Biochemical Pharmacology.

3. Characterization of recurrent UMOD variants (p.C255Y and p.Q316P) in a Galician cohort: Genotype–phenotype correlation and clinical implications. (2025). Nefrología.

4. Characterization of the functional component in human milk and identification of the molecular mechanisms undergoing prematurity. (2025). Clinical Nutrition.

5. HNF1B transcription factor: Key regulator in renal physiology and pathogenesis. (2025).

Jian Feng | Clinical Medicine | Best Researcher Award

Dr. Jian Feng | Clinical Medicine | Best Researcher Award

Doctor | The General Hospital of Western Theater Command | China

Dr. Jian Feng is an Attending Physician at the Intensive Care Unit of The General Hospital of Western Theater Command in Chengdu, Sichuan Province, China. He earned his medical degree and completed advanced training in critical care medicine, with a focus on sepsis, multiple organ failure, acute respiratory distress syndrome, and altitude sickness. Dr. Feng has led and participated in multiple provincial- and national-level research projects, including studies on ICU-acquired weakness, the role of curcumin in skeletal muscle preservation at high altitudes, and innovative interventions in critical care. He has published extensively, with over 11 SCI-indexed papers and numerous Chinese core journal articles as first or corresponding author, including high-impact works in Asian Journal of Surgery, Journal of Inflammation Research, and Frontiers in Cellular and Infection Microbiology. His contributions extend to medical innovation, holding multiple invention and utility model patents, and co-authoring the monograph Clinical Nutritional Therapy for Neurocritical Care. Dr. Feng has received recognition for his research and clinical excellence, including awards for innovation and translational medicine. Beyond his research, he serves as a reviewer for prestigious journals such as Heliyon and Medical Science Monitor, demonstrating his commitment to advancing scientific rigor and critical peer review in the field of critical care medicine. His work combines clinical expertise with innovative research, reflecting a dedication to improving patient outcomes and contributing to the scientific community at both national and international levels. He has 51 citations from 20 documents with an h-index of 4.

Profiles: Scopus | ORCID

Publications

1. Wang, M., Huang, B., Chen, J., Rui, Z., Li, J., Fang, S., Fan, L., Feng, J., & Li, F. (2025). Artificial intelligence and machine learning in the research and application status of ICU-acquired weakness.

2. Liu, J., Xu, Z., Luo, S., Bai, Y., Feng, J., & Li, F. (2024). Risk factors for ICU-acquired weakness in sepsis patients: A retrospective study of 264 patients.

3. Tan, J., Huang, B., Luo, S., Li, R., Hou, J., Zhang, R., Wang, L., Liu, Y., Li, F., & Feng, J. (2024). A rare case of severe pneumonia combined with septic shock caused by Nocardia amamiensis.

4. Luo, H., Feng, J., Xue, G., Zhang, Y., Li, Y., Huang, X., Chen, X., You, S., Dong, H., & Li, L. (2023). Comparative efficacy and acceptability of 12 phosphorus-lowering drugs in adults with hyperphosphatemia and chronic kidney disease: A systematic review and network meta-analysis.

5. Luo, S., Wang, L., Xu, Z., Liu, J., Zhang, W., Feng, J., & Li, F. (2023). Isolation, identification and biological characteristics of phage vB-KpnP1 for carbapenem-resistant Klebsiella pneumoniae.